Sirolimus to prevent recurrent squamous cell skin cancer, The Visual Abstract

swapnil hiremath

November 26, 2018

By NSMC graduate, Angel Ortiz

Tweet Feed

RT @johnholian: #nephJC As I've yet to prescribe a SGLT2i for anyone, I'm v mindful of @Sarah_Finer comments so far. But I can't he… https://t.co/Sd9FZeJJI3
about a day ago
RT @Sarah_Finer: Final thought from me. Glycaemic benefit from SGLT2i not huge/dramatic, so almost always an add-on drug. No need fo… https://t.co/0XO0SIFqYj
about a day ago
Until next time…thank you and good night! #NephJC
about a day ago
Please also sign up for our weekly newsletter at https://t.co/5aumn8ImwF #NephJC Looking for some #NephJC swag? Or… https://t.co/9HUmVZ3cQB
about a day ago
Thanks again to @drlovygaur for the summary and @MarioFunesMD for the VA. #NephJC
about a day ago
RT @VladoPerkovic: @werner02 @NephJC Yes, we need to learn more about how to watch for and manage DKA. But note 11 cases out of 5000 p… https://t.co/brH9K3Ybp4
about a day ago
Thanks for joining us tonight and for contributing to the discussion. #NephJC
about a day ago
RT @toates_19: t3: This is _surely_ the point: where in European health systems will prescribing lie with these drugs? Strikes me… https://t.co/IVSb5k6pp6
about a day ago
RT @logiebear111: @ThePeanutKidney @daviesmd3 @NephJC on this premise, i propose a trial of SGLT2i in IgAN 😂 #NephJC
about a day ago
Final few minutes: what are your take-home points? #NephJC
about a day ago
T3 How do you envisage these results will change your clinical practice? #NephJC
about a day ago
RT @Sarah_Finer: @logiebear111 @NephJC GPs already doing a great job doing most SGLT2i prescribing in east London. We supervise/advi… https://t.co/DupdzHX7QW
about a day ago
RT @logiebear111: @NephJC Many diabetic patients don’t regularly see a diabetologist or endocrinologist so who will prescribe and monitor SGLT2i? #nephjc
about a day ago
T3: Any other thoughts on the strengths and limitations? #NephJC
about a day ago
T3 Are you reassured by the safety data, particularly that relating to amputations? #NephJC
about a day ago
T3: This raises a question of generalisability and to consider at what GFR (if any) would one not use or stop an SGLT2i. #NephJC
about a day ago
T3: Limitations include 1. Premature termination of the trial limited the power for at least some secondary outcome… https://t.co/iN6D9OvCYN
about a day ago
T3: Strengths of the study include 1. The primacy given to renal outcomes 2. Benefit over and above RAS blockade wa… https://t.co/JoptkuL3fF
about a day ago
RT @VladoPerkovic: @HotKidneyAction The question the IDMC faced was whether additional knowledge gained over a further year or two was… https://t.co/8ly0AKTDKx
about a day ago
T3: Here's a summary of some future SGLT2i trials. Which ones are you excited about? https://t.co/5q6XUPnSUM
about a day ago